Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal Phase III Study Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant
MENLO PARK, Calif. & BARCELONA, Spain --(BUSINESS WIRE)--Oct. 8, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced the first presentation of results from RESOLVE II, a randomized,
View HTML
Toggle Summary Intersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant
MENLO PARK, Calif. & CHICAGO --(BUSINESS WIRE)--Sep. 9, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced presentation of a meta-analysis from two randomized studies evaluating the safety
View HTML
Toggle Summary Today's Research Report Coverage on Medical Equipment Stocks -- Lantheus, Intersect ENT, CHF Solutions, and ReWalk Robotics
NEW YORK , August 25, 2017 /PRNewswire/ -- If you want a Stock Review on LNTH, XENT, CHFS, or RWLK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Today's attention is focused onto the Medical Appliances and Equipment industry, which is
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2017 Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2017 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2017 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 1, 2017-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2017 .
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2017 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its second quarter on August 1, 2017 .
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2017 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its second quarter on August 1, 2017.
View HTML
Toggle Summary Intersect ENT Reports First Quarter 2017 Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2017 .
View HTML
Toggle Summary Intersect ENT to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT) a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that management is scheduled to present an overview of the company's business at the Bank of America
View HTML
Toggle Summary Intersect ENT to Report First Quarter 2017 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its first quarter on May 2, 2017 .
View HTML